Impact of tumor biomarkers and patient’s age on the “disease stage” in women with breast cancer in Erbil city

  • Showan Salam Marouf Department of Oral Diagnosis, College of dentistry, Hawler Medical University, Erbil, Iraq.
  • Jangi Sh. Muhialdin Department of Internal medicine, College of medicine, Hawler Medical University, Erbil, Iraq.
Keywords: Breast cancer, Disease stage


Background and objective: Female breast cancer is the most commonly diagnosed cancer worldwide, affecting more than one million women annually. The objectives of this study were, firstly, to evaluate the effects of breast cancer biomarkers such as human epidermal growth factor receptor-2and hormone receptor status on the stage of breast cancer at the time of presentation, and secondly, to assess the role of “women’s age” on the level of biomarker expressions and on the advancement in breast cancer disease stage at the time of diagnosis in a sample of women diagnosed with breast cancer in Erbil City.  

Methods: A retrospective analysis of medical records of women affected with breast cancer was performed from January 2013 to April 2014. Cancer staging was done based on the histopathological reports according to the American Joint Committee on Cancer TNM staging system. Patients were classified to either hormone receptor/human epidermal growth factor receptor-2 positive or negative based on immunohistochemistry or FISH analysis.    

Results: The mean age (+SD) at diagnosis was 48.9 (+12.4) years. About a quarter of breast cancer cases were diagnosed in young women aged less than 40 years, who had a proportionally more hormone receptor negativity and human epidermal growth factor receptor-2 over-expression, and a significantly more advanced cancer stage at time of diagnosis compared to their older counterparts.

Conclusion: Breast cancer biomarkers have huge impacts on disease stage, and are greatly affected by age of women at time of diagnosis of breast cancer.


Gargiullo P, Wingo PA, Coates RJ, Thompson TD. Recent trends in mortality rates for four major cancers, by sex and race/ethnicity – United States, 1990-1998. MMWR 2002; 51(03):49-53.

Boyle P, Howell A. The globalisation of breast cancer. Breast Cancer Res 2010;12Suppl 4:S7.

Narod SA. Breast cancer in young women. Nat Rev ClinOncol 2012;9:460-70.

Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533.

Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 1996;78:1838-43.

Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer InstMonogr 1994:35-42.

Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000;320:474-8.

Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 to stage III breast cancer in young women. J Am CollSurg 2000;190:523-9.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J ClinOncol 2008;26:3324-30.

Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012;131:1061-6.

Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th Edition. New York: Springer; 2010.

Anders CK, Johnson R, Litton J. Breast cancer before age 40 years. SeminOncol 2009;36: 237-49.

Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009;4:e7695.

Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999;91:1241-7.

Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001;10:83-7.

Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008;261:21-5.

Gomes MC, Kotsopoulos J, de Almeida GL, Costa MM, Vieira R, FilhoFde A, et al. The R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer ClinPract 2012;10:3.

Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer 2010;116:2549-59.

Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early- onset breast cancer. Implications for risk prediction. Cancer1994;73:643-51.

Claus EB. The genetic epidemiology of cancer. Cancer Surv1995;25:13-26.

Narod SA. Breast cancer in young women. Nat Rev ClinOncol 2012;9:460-70.

Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.

Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007;31:1031-40.

Nair MK, Sankaranarayanan R, Nair KS, Amma NS, Varghese C, Padmakumari G, Cherian T. Overall survival from breast cancer in Kerala, India, in relation to menstrual, reproductive, and clinical factors. Cancer 1993;71:1791-6.

Moss SM, Cuckle H, Evans A, Johns L, Waller M, BobrowL,et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006; 368 (9552):2053-60.

Hoerger TJ, Ekwueme DU, Miller JW, Uzunangelov V, Hall IJ, Segel J, et al. Estimated effects of the National Breast and Cervical Cancer Early Detection Program on breast cancer mortality.Am J Prev Med 2011;40(4):397-404.

Duffy SW, Tabár L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 2002; 95(3):458-69.

Jonsson H, Nyström L, Törnberg S, Lenner P. Service screening with mammography of women aged 50-69 years in Sweden: effects on mortality from breast cancer. J Med Screen 2001;8 (3): 152-60.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. ProcNatlAcadSci USA 2001;98:10869-74.

Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. ProcNatlAcadSci USA 2003;100:10393-8.

El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006;6:194.

Bharat A, Aft RL, Gao F, Margenthaler JA. Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer. J SurgOncol 2009;100:248-51.

Arvold ND, Taghian AG, Niemierko A, AbiRaad RF, Sreedhara M, Nguyen PL, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J ClinOncol 2011;29:3885-91.

de la Rochefordiere A, Asselain B, Campana F. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43.

Adami HO, Malker B, Holmberg L. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315:559-63.

Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, et al. Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer 2002;3:65-72.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.

Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.

Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439-43.

Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, et al. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. PatholOncol Res 2011;17:753-8.

Carvalho FM, Bacchi LM, Santos PP, Bacchi CE. Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients. Clinics (Sao Paulo) 2010;65:1033-6.

Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J ClinOncol 2011;29:e18-20.

Crowe JP Jr, Gordon NH, Shenk RR. Age does not predict breast cancer outcome. Arch Surg 1994;129:483-7.

Ezzat A, Raja MA, Zwaan F, Brigden M, Rostom A, Bazarbashi S. The lack of age as a significant prognostic factor in non-metastatic breast cancer. Eur J SurgOncol 1998;24:23-7.

Figueiredo JC, Ennis M, Knight JA, McLaughlin JR, Hood N, O'Malley F, et al. Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res Treat 2007;105:69-80.

Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. ClinCancer Res 2012;18:1341-51.

How to Cite
Marouf, S., & Muhialdin, J. (2018). Impact of tumor biomarkers and patient’s age on the “disease stage” in women with breast cancer in Erbil city. Zanco Journal of Medical Sciences (Zanco J Med Sci), 19(2), 1019 - 1028.
Original Articles